PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Olbrich, L.* ; Verghese, V.P.* ; Franckling-Smith, Z.* ; Sabi, I.* ; Ntinginya, N.E.* ; Mfinanga, A.* ; Banze, D.* ; Viegas, S.* ; Khosa, C.* ; Semphere, R.* ; Nliwasa, M.* ; McHugh, T.D.* ; Larsson, L.* ; Razid, A.* ; Song, R.* ; Corbett, E.L.* ; Nabeta, P.* ; Trollip, A.* ; Graham, S.M.* ; Hoelscher, M. ; Geldmacher, C.* ; Zar, H.J.* ; Michael, J.S.* ; Heinrich, N.*

Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries.

Lancet Infect. Dis. 24, 140-149 (2023)
Publ. Version/Full Text DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
BACKGROUND: Childhood tuberculosis remains a major cause of morbidity and mortality in part due to missed diagnosis. Diagnostic methods with enhanced sensitivity using easy-to-obtain specimens are needed. We aimed to assess the diagnostic accuracy of the Cepheid Mycobacterium tuberculosis Host Response prototype cartridge (MTB-HR), a candidate test measuring a three-gene transcriptomic signature from fingerstick blood, in children with presumptive tuberculosis disease. METHODS: RaPaed-TB was a prospective diagnostic accuracy study conducted at four sites in African countries (Malawi, Mozambique, South Africa, and Tanzania) and one site in India. Children younger than 15 years with presumptive pulmonary or extrapulmonary tuberculosis were enrolled between Jan 21, 2019, and June 30, 2021. MTB-HR was performed at baseline and at 1 month in all children and was repeated at 3 months and 6 months in children on tuberculosis treatment. Accuracy was compared with tuberculosis status based on standardised microbiological, radiological, and clinical data. FINDINGS: 5313 potentially eligible children were screened, of whom 975 were eligible. 784 children had MTB-HR test results, of whom 639 had a diagnostic classification and were included in the analysis. MTB-HR differentiated children with culture-confirmed tuberculosis from those with unlikely tuberculosis with a sensitivity of 59·8% (95% CI 50·8-68·4). Using any microbiological confirmation (culture, Xpert MTB/RIF Ultra, or both), sensitivity was 41·6% (34·7-48·7), and using a composite clinical reference standard, sensitivity was 29·6% (25·4-34·2). Specificity for all three reference standards was 90·3% (95% CI 85·5-94·0). Performance was similar in different age groups and by malnutrition status. Among children living with HIV, accuracy against the strict reference standard tended to be lower (sensitivity 50·0%, 15·7-84·3) compared with those without HIV (61·0%, 51·6-69·9), although the difference did not reach statistical significance. Combining baseline MTB-HR result with one Ultra result identified 71·2% of children with microbiologically confirmed tuberculosis. INTERPRETATION: MTB-HR showed promising diagnostic accuracy for culture-confirmed tuberculosis in this large, geographically diverse, paediatric cohort and hard-to-diagnose subgroups. FUNDING: European and Developing Countries Clinical Trials Partnership, UK Medical Research Council, Swedish International Development Cooperation Agency, Bundesministerium für Bildung und Forschung; German Center for Infection Research (DZIF).
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
56.300
0.000
1
1
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Pulmonary Tuberculosis; Expression; Children; Mtb/rif
Language english
Publication Year 2023
HGF-reported in Year 2023
ISSN (print) / ISBN 1473-3099
e-ISSN 1474-4457
Journal The Lancet. Infectious diseases
Quellenangaben Volume: 24, Issue: 2, Pages: 140-149 Article Number: , Supplement: ,
Publisher Elsevier
Publishing Place 125 London Wall, London, England
Reviewing status Peer reviewed
Institute(s) Research Unit Global Health (UGH)
POF-Topic(s) 30205 - Bioengineering and Digital Health
Research field(s) Enabling and Novel Technologies
PSP Element(s) G-540001-003
Grants Cepheid
Beckman Coulter
German Center for Infection Research (DZIF)
Bundesministerium fur Bildung und Forschung
Swedish International Development Cooperation Agency
UK Medical Research Council
EU
European and Developing Countries Clinical Trials Partnership (EDCTP2 programme)
DOI 10.1016/S1473-3099(23)00491-7
WOS ID 001167256500001
Scopus ID 85175247899
PubMed ID 37918414
Erfassungsdatum 2023-11-28
[➜Report correction]